Image of nurses' hands at computer keyboard
Credit: Getty Images

» COMS Interactive LLC has introduced Outcomes IQ™. This software will extend the Daylight IQ product suite, the company said. It allows for data for large chains and facilities to include hospital re-admission rates, mortality rates and average number of Medicare referrals. Components of the software include an Automated Disease Care Guide Library and a Dynamic Nursing Assessment. 

» HealthMEDX announced a new Medical Advisory Board comprising physicians in post-acute facilities, health systems and private practice. The board will help with product development priorities, HealthMedX CEO Pamela Pure said.

» Acorda Therapeutics Inc. acquired two assets from NeurogesX Inc. The company paid $8 million to acquire development and commercialization rights for Qutenza® and NP-1998 in the United States, Canada and Latin America. Qutenza is approved by the FDA for the management of pain associated with postherpetic neuralgia. The company also acquired NP-1998, a prescription strength capsaicin topical solution, for the treatment of
neuropathic pain.

» Optimus EMR released its second generation EMAR, a module for patient care used constantly for medication delivery and related activities. New features include the ability to function during an Internet outage for “mission critical activities.” Other new functions include incorporating bi-directional information share through pharmacy electronic interfaces and complete medication information available at the time of administration. 

» The Nurses Improving Care for Healthsystem Elders program has selected HealthcareSource for e-learning content and webinars. The NICHE Knowledge Center offers tools and resources for nurses and providers, and the HealthcareSource NetLearning Learning Management System software will let NICHE member organizations access content.

» Drive Medical said it has agreed to stop importing and selling Freedom 210 and Freedom 220 CPAP masks, per an agreement with the International Trade Commission, after a patent rights claim.